All In Biotech

Drug Trial Radar · NCT04206163

Somatostatin Receptor Imaging in Acute Myocarditis and Cardiac Sarcoidosis

Somatostatin Receptor Imaging in Inflammatory Heart Disease

Last checked: Nov 20, 2026Latest source record: Sep 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

78

Actual

Start

Jan 20, 2020

Primary completion

Jun 24, 2024

Study completion Jun 24, 2024

Sponsor

Lead sponsor
Vastra Gotaland RegionGovernment (non-federal)
Sponsor type
Government (non-federal)
First posted
Dec 20, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This prospective imaging study investigates the diagnostic ability of Gallium-68 DOTA-TOC (68Ga-DOTA-TOC) positron emission tomography/computed tomography (PET/CT) in the clinical work-up of patients with 1) clinically suspected acute myocarditis (n=30-40) and 2) clinically suspected cardiac sarcoidosis (n=30-40) using clinical diagnostic criteria as well as endomyocardial biopsy as reference. Furthermore, 68Ga-DOTA-TOC PET/CT findings will be compared with results from contrast-enhanced magnetic resonance imaging (MRI) and in case of cardiac sarcoidosis even Fluorine-18 fluorodeoxyglucose (18F-FDG) PET/CT, which are both performed as part of the clinical routine work-up.

Conditions

  • Acute Myocarditis
  • Cardiac Sarcoidosis

Interventions

  • 68Ga-DOTA-TOC PET/CTDiagnostic test

    Somatostatin receptor imaging

  • Blood sampleBiological

    Analysis of inflammatory biomarkers

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sensitivity of 68Ga-DOTA-TOC PET/CT versus contrast-enhanced MRI in patients with clinically suspected acute myocarditis (using clinical diagnostic criteria as well as endomyocardial biopsy as reference)Time frame: Completion of enrollment, approximately 2 years
  2. Specificity of 68Ga-DOTA-TOC PET/CT versus contrast-enhanced MRI in patients with clinically suspected acute myocarditis (using clinical diagnostic criteria as well as endomyocardial biopsy as reference)Time frame: Completion of enrollment, approximately 2 years
  3. Sensitivity of 68Ga-DOTA-TOC PET/CT versus contrast-enhanced MRI and 18F-FDG PET/CT in patients with clinically suspected cardiac sarcoidosis (using clinical diagnostic criteria as well as endomyocardial biopsy as reference)Time frame: Completion of enrollment, approximately 5 years
  4. Specificity of 68Ga-DOTA-TOC PET/CT versus contrast-enhanced MRI and 18F-FDG PET/CT in patients with clinically suspected cardiac sarcoidosis (using clinical diagnostic criteria as well as endomyocardial biopsy as reference)Time frame: Completion of enrollment, approximately 5 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sahlgrenska University Hospital

    Gothenburg, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.